Century Therapeutics Inc 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the quarterly period ended March 31, 2026OR For the transition period from _______ to _______Commission File Number: 001-40498 Century Therapeutics,Inc. (Exact Name of Registrant as Specified in its Charter) Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of theSecurities Exchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant was requiredto file such reports), and (2)has been subject to such filing requirements for the past 90days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12months (or for suchshorter period that the registrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer,smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “acceleratedfiler,” “smaller reporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☒ Accelerated filer☐Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transitionperiod for complying with any new or revised financial accounting standards provided pursuant to Section13(a)of theExchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).Yes☐No☒ As of May 1, 2026 the registrant had 180,354,809 shares of common stock, $0.0001 par value per share, outstanding. Table of Contents PARTI.FINANCIAL INFORMATION Item 1. Unaudited Consolidated Financial Statements:5Consolidated Balance Sheets as of March 31, 2026 (unaudited) and December31, 20255Consolidated Statements of Operations and Comprehensive Income (Loss) forthe three months ended March 31, 2026 and 2025 (unaudited)6Consolidated Statements of Changes in Stockholders’ Equity for the threemonths ended March 31, 2026 and 2025 (unaudited)7Consolidated Statements of Cash Flows for the three months ended March 31,2026 and 2025 (unaudited)8Notes to Unaudited Consolidated Financial Statements9Item 2.Management’s Discussion and Analysis of Financial Condition and Results ofOperations27Item 3. Quantitative and Qualitative Disclosures About Market Risk39Item 4. Controls and Procedures40 Item 1.Legal Proceedings41Item1A.Risk Factors41Item 2.Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchasesof Equity Securities41Item 3.Defaults Upon Senior Securities41Item 4.Mine Safety Disclosures41Item 5. Other Information41Item 6. Exhibits43Signatures44 CAUTIONARY NOTEREGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q and the documents incorporated by reference hereincontain forward-looking statements that involve substantial risks and uncertainties. Allstatements, other than statements of historical facts, included in this Quarterly Report on Form10-Q or the documents incorporated by reference herein regarding our strategy, futureoperations, future financial position, future revenues, projected costs, prospects, plans andobjectives of management are forward-looking statements. The words “anticipate,” “believe,”“estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “would,” “could,” “should,”“potential,” “seek,” “evaluate,” “pursue,” “continue,” “design,” “impact,” “affect,” “forecast,” “target,”“outlook,” “initiative,” “objective,” “designed,” “priorities,” “goal,” or the negative of such terms andsimilar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are based on assumptionsand expectations that may not be realized and are inherently subject to risks, uncertainties andother factors, many of which cannot be predicted with accuracy and some of which might noteven be anticipated. The forward-looking statements in this Quarterly Report on Form 10-Q include, among otherthings, statements about: ●our ability to raise additional capital to fund our operations and continue the developmentof our current and future product candidates;●the early preclinical and clinical nature of our business and our ability to successfullyadvance our current and future product candidates, through development activities,preclinical studies, and clinical trials;●our ability to generate revenue from future product sales and our ability to achieve andmaintain profitability;●the accuracy of our projections and estimates regarding our expenses, capitalrequirements, cash utilization, and need for additional fin